POM121 transmembrane nucleoporin like 4, pseudogeneGenealiases: []
Q-omics provides the consensus-scored POM121L4P profile across patient tissues and cancer cell-line models. POM121L4P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, POM121L4P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, POM121L4P RNA expression shows 6,548 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, HNSC, and STAD as cancer lineages where POM121L4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POM121L4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POM121L4P survival associations across molecular data types. POM121L4P RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POM121L4P RNA expression–survival associations across cancer types. High POM121L4P expression shows unfavorable associations in LUAD, MESO, THCA, UCEC and LIHC, but favorable associations in ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for POM121L4P RNA expression.
This table summarizes POM121L4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for POM121L4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POM121L4P shows lower tumor expression in BRCA, LUAD and KIRC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher POM121L4P RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .025).
This table shows molecular features associated with POM121L4P in patient tissues and cancer cell lines. In patient samples, POM121L4P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
